PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 701–800 of 1,001
Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
Min, L. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.10.002 · Cited by 16
Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors
Gnanendran, S., Turner, L. M., Miller, J. A., Hwang, S. J. E., & Miller, A. C. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0721-7 · Cited by 18
New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis
Pane, K., Mirabelli, P., Coppola, L., Illiano, E., Salvatore, M., & Franzese, M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00600 · Cited by 17
“Immunotherapy of Bladder Cancer: New Frontiers During the 1990s, the immune checkpoint key proteins, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death-ligand 1 (PDL1), revolutionized cancer therapy (Korman et al., 2006; Okazaki and Honjo, 2007).”
BackgroundYokohama, K., Asai, A., Matsui, M., Okamoto, N., Yasuoka, H., Nishikawa, T., Ohama, H., Tsuchimoto, Y., Inoue, Y. H., Fukunishi, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71561-2 · Cited by 16
Immune regulation in renal inflammation
Neumann, K., & Tiegs, G. (2021) · Cell and Tissue Research · doi:10.1007/s00441-020-03351-1 · Cited by 17
Tang, H., & Wang, X. (2021) · BioMed Research International · doi:10.1155/2021/7973123 · Cited by 16
RetractedSaito, Y., Fujiwara, Y., Shinchi, Y., Mito, R., Miura, Y., Yamaguchi, T., Ikeda, K., Urakami, S., Nakashima, Y., Sakagami, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15442 · Cited by 18
Liu, Q., Lu, J., Wang, X. H., Qu, B.-J., Li, S. R., & Kang, J. R. (2014) · Genetics and Molecular Research · doi:10.4238/2014.september.26.4 · Cited by 16
“…studies suggest that the PD-1/PD-L1 inhibition pathway participates in the body’s immune tolerance caused by tumors and infection of viruses such as HBV, HCV, and HIV, and also plays an important role in implant immune tolerance (Dong and Chen, 2006; Okazaki and Honjo, 2007; Parekh et al., 2009).”
BackgroundBender, C., Hassel, J. C., & Enk, A. (2016) · Oncology Research and Treatment · doi:10.1159/000446716 · Cited by 19
Mishra, D. K., Rocha, H. J., Miller, R. A., & Kim, M. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-34983-7 · Cited by 16
Intellectual property issues of immune checkpoint inhibitors
Storz, U. (2015) · mAbs · doi:10.1080/19420862.2015.1107688 · Cited by 17
“PD-1 was discovered by Kyoto University scientist Tasuku Honjo in the 1990s.(14) However, the role of PD-1 was not immediately clear, although Professor Honjo deduced, from PD-1 knockout mice who developed lupus-like symptoms, that PD-1 has a negative regulatory effect on the immune system.”
MethodProgrammed death-ligand 1 expression in the immune compartment of colon carcinoma
Yılmaz, O., Pankaj, A., Neyez, A., Rickelt, S., Taylor, M. S., Lang, E. R., Leijssen, L. G. J., Dinaux, A. M., Shroff, S. G., Crotty, R. K., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01128-1 · Cited by 15
Guo, R., Peng, J.-Z., Li, Y., & Li, X. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2112007 · Cited by 17
“The PD-1 receptor transmits inhibitory signals to T cells through binding to its ligands PD-L1 and PD-L2 [33].”
BackgroundHo, M. P., & Bonavida, B. (2024) · Cells · doi:10.3390/cells13100864 · Cited by 18
“Specifically, the discovery of singular receptors was reported, namely, cytotoxic T lymphocyte antigen 4 (CTLA-4) [17] and the subsequent breakthroughs with the programed cell death 1 (PD-1) receptor (CD279) and its ligands PD-L1 (CD274) and PD-L2 (CD273) [18,19].”
BackgroundWu, T., Wu, S., Gao, H., Liu, H., Feng, J., & Yi, G. (2024) · European Journal of Histochemistry · doi:10.4081/ejh.2024.4098 · Cited by 17
Harnessing m1A modification: a new frontier in cancer immunotherapy
Wang, X., Ma, X., Chen, S., Fan, M., Jin, C., Chen, Y., Wang, S., Wang, Z., Meng, F., Zhang, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1517604 · Cited by 24
Li, D., Xu, J., Wang, Z., Gong, Z. L., Liu, J., Zheng, Y. T., Li, J. J., & Li, J. (2017) · mAbs · doi:10.1080/19420862.2017.1296612 · Cited by 15
“Programmed death-1 receptor (PD-1), an immune inhibitory receptor expressed on activated B cells, T cells and myeloid cells,(4) has critical roles in regulating stimulatory and inhibitory signals in the immune system.(5) PD-1 belongs to the CD28/CTLA-4 subfamily within the immunoglobulin super family.”
BackgroundNeurotoxicity of antibodies in cancer therapy: A review
Horta, E. S., Bongiorno, C. M., Ezzeddine, M. A., & Neil, E. C. (2019) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2019.105566 · Cited by 16
Singh, L., Singh, M. K., Rizvi, M. M. A., Pushker, N., Bakhshi, S., Sen, S., & Kashyap, S. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315490 · Cited by 15
The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma
Takabe, P., Siiskonen, H., Rönkä, A., Kainulainen, K., & Pasonen‐Seppänen, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.811434 · Cited by 18
The role of programmed death ligand 1 pathway in persistent biomaterial-associated infections
Magryś, A., Paluch-Oleś, J., Bogut, A., Kiełbus, M., Plewik, D., & Kozioł-Montewka, M. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-5022-7 · Cited by 16
Akiyoshi, H., Chung, J., Tomihari, M., Cruz, P. D., & Ariizumi, K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903250 · Cited by 15
“Although neither SD-4– nor PD-1–expressing T cells were present in the DLN of mice sensitized alone (day 0, just prior to challenge) and day 1 following challenge, positive cells were found in DLNs 3 d postchallenge (Fig.”
BackgroundInfluentialInhibitory checkpoints in human natural killer cells: IUPHAR Review 28
Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., Tumino, N., Pietra, G., Mingari, M. C., & Moretta, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15081 · Cited by 17
“Despite ITIM is often associated with inhibitory receptors (including KIRs and NKG2A) being required for the activation of the inhibitory cascade, the tyrosine residue in the ITSM has been shown to be essential for PD-1 inhibitory function (Okazaki, Maeda, Nishimura, Kurosaki, & Honjo, 2001).”
BackgroundInfluentialBertaglia, V., Vallone, S., Pacchiana, M. V., & Novello, S. (2017) · Lung Cancer Management · doi:10.2217/lmt-2017-0011 · Cited by 15
裕), (., Gonzalez, L., Kiwan, G., 佳), (., Langford, J. T., 明杰), (., 喜翔), (., 良輔), (., Yatsula, B., 正), (., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316380 · Cited by 13
Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer
Li, N., Wang, G., Hou, X., Tai, R., Huang, S., He, Z., Lei, L., Xu, S., & Yang, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108803 · Cited by 15
Johnson, J., Kim, S., Sam, P. K., Asokan, R., Cari, E. L., Bales, E. S., Luu, T., Perez, L., Kallen, A. N., Nel‐Themaat, L., et al. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13649 · Cited by 15
Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment
Lv, J., Jiang, Z., Yuan, J., Zhuang, M., Guan, X., Liu, H., Yin, Y., Ma, Y., Liu, Z., Wang, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093716 · Cited by 17
PD-1Hi CAR-T cells provide superior protection against solid tumors
Sailer, C. J., Hong, Y., Dahal, A., Ryan, A. T., Mir, S., Gerber, S. A., Reagan, P. M., & Kim, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187850 · Cited by 18
Dioken, D. N., Ozgul, İ., Yılmazbilek, İ., Yakicier, M. C., Karaca, E., & Erson-Bensan, A. E. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03543-y · Cited by 15
“Hence, PD-1/PD-L1 signal transduction is critical for autoimmunity, antiviral responses, and antitumoral T-cell responses [6].”
BackgroundRNA therapeutics in cancer treatment
Nguyen, M. N., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.003 · Cited by 14
Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future
Wei, H., Dong, C., & Li, X. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00462 · Cited by 21
“88 The US FDA approved nivolumab (PD-1 inhibitor) in 2017 for use as a second-line therapy for patients with severe HCC after the receipt of sorafenib, a tyrosine kinase inhibitor (TKI).”
BackgroundBrun, S. S., Hansen, T. F., Wen, S. W. C., Nyhus, C. H., Bertelsen, L., Jakobsen, A. K. M., Hansen, T. S., & Nederby, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-59791-0 · Cited by 14
Ye, Z., Cheng, P., Huang, Q., Hu, J., Huang, L., & Hu, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1388176 · Cited by 15
“Nevertheless, notwithstanding the therapeutic promise, the response rate to immune checkpoint therapy remains modest, with resistance posing a formidable challenge (171, 172).”
BackgroundMatsui, K., Tani, R., Yamasaki, S., Ito, N., Hamada, A., Shintani, T., Otomo, T., Tokumaru, K., Yanamoto, S., & Okamoto, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116077 · Cited by 17
“Subsequently, the growth of murine melanoma transplanted into PD-1 knockout mice or transplanted mouse tumors was inhibited by antibodies that block the PD-1/PD-L1 pathway, indicating that this pathway plays a central role in cancer immune escape [19,20].”
BackgroundOzeki, Y., Hirayama, Y., Takii, T., Yamamoto, S., Kobayashi, K., & Matsumoto, S. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.051 · Cited by 14
Bergström, S., Uzunel, M., Talme, T., Bergdahl, E., & Sundqvist, K. (2014) · Immunology · doi:10.1111/imm.12424 · Cited by 15
Immunotherapy-Related Acute Kidney Injury
Manohar, S., Jhaveri, K. D., & Perazella, M. A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.07.006 · Cited by 14
Tohn, R., Blumenfeld, H., Haeryfar, S. M. M., Veerapen, N., Besra, G. S., Porcelli, S. A., & Delovitch, T. L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04323.x · Cited by 14
Kan‐o, K., Matsumoto, K., Asai, Y., Fukuyama, S., Hamano, S., Seki, N., Nakanishi, Y., & Inoue, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.082 · Cited by 15
Takizawa, S., Kaneyama, T., Tsugane, S., Takeichi, N., Yanagisawa, S., Ichikawa, M., Yagita∥, H., Kim, B. S., & Koh, C. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.018 · Cited by 15
“The pathway consisting of programmed death-1 (PD-1) receptor (CD279) and its ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273), delivers inhibitory signals that regulate the balance among T-cell activation, tolerance, and immune-mediated tissue damage (Okazaki and Honjo, 2007; Sharpe et al., 2007; Nurieva et al.,…”
BackgroundIncreased expression of PD‐L1 and PD‐L2 in dermal fibroblasts from alopecia areata mice
Li, Y., Kilani, R. T., Pakyari, M., Leung, G., Nabai, L., & Ghahary, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26134 · Cited by 14
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics
Messerschmidt, J. L., Bhattacharya, P., & Messerschmidt, G. L. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0625-2 · Cited by 16
Samancı, N. Ş., Ozan, T., Çelik, E., & Demirelli, F. H. (2019) · JCO Oncology Practice · doi:10.1200/jop.19.00438 · Cited by 14
Yang, W., Men, P., Xue, H., Jiang, M., & Luo, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00197 · Cited by 16
Mani, M., Park, J. W., & Martin, T. F. J. (2025) · Cancers · doi:10.3390/cancers17111747 · Cited by 18
“For instance, in autoimmune conditions like type 1 diabetes [11] and multiple sclerosis [12], disruptions in the PD-1 pathway can result in a loss of tolerance, allowing self-reactive T cells to attack the body’s own tissues [13].”
Rituximab in steroid-refractory immune-related pancreatitis: a case report
Santoro, A., Masini, S., Cavina, R., Tronconi, M. C., & Vincenzo, F. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1205720 · Cited by 13
Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond
Patel, M., Hudson, O., Han, J., Kondapalli, L., Arora, G., Hawi, R., Andrikopoulou, E., Estes, C., Johnson, A. M., & Lenneman, C. G. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01130-y · Cited by 15
“The binding of PD-1 to PD-L1 and PD-L2 suppressed the activation and function of T-cells which translates into the downregulation of the immune response [11, 12].”
BackgroundMalik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 14
The anterior chamber of the eye technology and its anatomical, optical, and immunological bases
Yang, S.-N., Shi, Y., & Berggren, P. (2024) · Physiological Reviews · doi:10.1152/physrev.00024.2023 · Cited by 14
PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Straube, J., Bukhari, S., Lerrer, S., WINCHESTER, R. J., Gartshteyn, Y., Henick, B. S., Dragovich, M. A., & Mor, A. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03259-5 · Cited by 15
“More severe side effects, such as the reactivation of latent infections, have also been reported [23, 24].”
BackgroundPeptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
Bojko, M., Wegrzyn, K. E., Sikorska, E., Ciura, P., Battin, C., Steinberger, P., Magiera‐Mularz, K., Dubin, G., Kulesza, A., Sieradzan, A. K., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101892 · Cited by 14
“Blocking the PD-1/PD-L1 pathway by the use of monoclonal antibodies has been shown to enhance antitumor T cell responses in many types of cancers [29,49]; however, there is still a need to search for compounds other than antibodies.”
BackgroundImmunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies
Kong, Y., Wang, X., & Qie, R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1347140 · Cited by 14
“Its primary role is to maintain peripheral tolerance (15).”
BackgroundNa, H., Im, K.-I., Kim, N., Lee, J., Gil, S., Min, G. J., & Cho, S. (2024) · iScience · doi:10.1016/j.isci.2024.109783 · Cited by 14
“38,39 Therefore, we explored if the levels of mRNAs encoding PD-L1 and PD-L2 varied by DSC IL-6 secretion status.”
BackgroundLee, W. J., Lee, Y. J., Shin, H. J., Won, C. H., Chang, S. E., Choi, J. H., & Lee, M. W. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000449 · Cited by 13
Lyu, M., Shen, Y., Beharee, N., Jin Wei, L. U., Deng, F., & Wang, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s245190 · Cited by 13
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan, W., Xiao, C., Lao, X., Zheng, L., & Kuang, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03637-1 · Cited by 14
“Upon ligation and tyrosine phosphorylation, these motifs recruit Src homology 2 domain-containing phosphatases SHP-1 and SHP-2 to dampen the activation of immune cells [27, 28].”
BackgroundRole of PD-L1 Expression during the Progression of Submucosal Gastric Cancer
Ubukata, Y., Ogata, K., Sohda, M., Yokobori, T., Shimoda, Y., Handa, T., Nakazawa, N., Kimura, A., Kogure, N., Sano, A., et al. (2020) · Oncology · doi:10.1159/000509033 · Cited by 15
“PD-L1/2 is found on the surface of cancer cells that bind to the immune checkpoint receptor PD-1 on the surface of cytotoxic T cells, thereby inactivating active T cells and evading immune recognition [11-13].”
BackgroundCOVID‐19, varying genetic resistance to viral disease and immune tolerance checkpoints
Goodnow, C. C. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12419 · Cited by 16
“That tolerance can be overcome, and switched into an immune response, by antibody-based drugs that block the inhibitory receptors responsible for key immune tolerance checkpoints: CTLA-4122 and PD-1.”
BackgroundInfluentialZhu, S., Liu, C., Dong, Y., Shao, J., Liu, B., & Shen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.788635 · Cited by 14
Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154338 · Cited by 15
Kroner, A., Schwab, N., Ip, C. W., Sommer, C., Wessig, C., Wiendl, H., & Martini, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.021 · Cited by 13
“A candidate molecule which might be involved in this regulation and keep the pathogenetic impact of the T-lymphocytes limited in the myelin mutants, is the co-inhibitory molecule “programmed death” (PD)-1 (CD279), a CD28-related receptor expressed on activated T- and B-lymphocytes (Okazaki and Honjo, 2007; Okazaki et…”
BackgroundInfluentialChen, Q., Hu, W., Xiong, H., Ying, S., Ruan, Y., Wu, B., & Lu, H. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0798-0 · Cited by 15
Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC
Olaoba, O. T., Ligali, F. C., Alabi, Z. O., Akinyemi, A. O., & Ayinde, K. S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188483 · Cited by 14
Prell, R. A., Halpern, W., & Rao, G. K. (2016) · International Journal of Toxicology · doi:10.1177/1091581815625596 · Cited by 15
“With regard to the potential risk on the developing offspring, several reports have demonstrated that PD-1-deficient mice and, to a lesser extent, PD-L1-deficient mice, develop strain dependent, spontaneous autoimmunity through loss of immune tolerance mechanisms.(43,44,50,64) In addition, polymorphisms in human PDCD1…”
BackgroundLenvatinib enhances antitumor immunity of anti-PD-1 antibody
Kato, Y. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02721-5 · Cited by 13
“However, subsequent analysis of a spontaneous lupus-like autoimmune disease in PD-1 deficient mice revealed that PD-1 is expressed on activated T and B cells in the periphery, and on thymocytes, and negatively regulates the immune responses of these immune cell populations [10].”
Oh, M., Park, H. S., Chae, D., Yu, A., Park, J. H., Heo, J., Cho, K., Kim, J., Lim, B., Kim, J.-M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02516-0 · Cited by 12
“6 Clinical blockade of this axis can trigger colitis, which resembles IBD, emphasizing its role in intestinal immune homeostasis.”
Immunotherapy for malignant mesothelioma: reality check
Thapa, B., Watkins, D. N., & John, T. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1241149 · Cited by 17
Tissue biomarkers of immune checkpoint inhibitor therapy
Davoudi, F., Moradi, A., Sadeghirad, H., & Kulasinghe, A. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12723 · Cited by 15
“30 The US Food and Drug Administration approved anti – PD-1 antibodies, including pembrolizumab, nivolumab and cemiplimab, as well anti – PD-L1 antibodies, such as atezolizumab, avelumab and durvalumab.”
BackgroundRecent advances in biomimetic nanodelivery systems for cancer Immunotherapy
Yang, J., Li, X., Li, T., Mei, J., & Chen, Y. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101726 · Cited by 21
“PD-L1 is also highly expressed in tumor cells, including lung cancer cells, colon cancer, etc [44].”
PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients
Wang, W., Shen, G., Wu, S., Song, S., Ni, Y., Suo, Z., Meng, X., Li, D., Zhou, L., Hao, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15006 · Cited by 15
Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma.
Kong, D., Liu, C., Miao, X., Wang, Y., Ding, X., & Gong, W. (2020) · PubMed · Cited by 12
Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1.
Wong, N. C. L., Cai, Y., Meszaros, L. K., Biersack, H., Cook, G., Ting, H. H., & Mottaghy, F. M. (2021) · PubMed · Cited by 12
Immune checkpoint inhibitors in kidney transplantation
Alzahrani, N., Jurdi, A. A., & Riella, L. V. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001036 · Cited by 14
“At the same time, working independently in Japan, Tasuku Honjo discovered programmed cell death protein-1 (PD-1), another immune regulatory protein [20,21], which led to a whole new discipline of anticancer immunotherapy leading them towin the 2018Nobel prize in Physiology and Medicine [22].”
Background今田, 道., Masuda, K., Satoh, R., Ito, Y., Goto, Y., Matsuoka, T., Endo, S., Nakamura, A., Kawamoto, H., & Takai, T. (2009) · International Immunology · doi:10.1093/intimm/dxp081 · Cited by 12
Immune engineering: From systems immunology to engineering immunity
Jiang, N. J. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.03.002 · Cited by 15
Li, T., Shi, Y., Sun, W., Wang, H., Wang, Q., & Jiang, Y. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.020 · Cited by 12
“Due to a wide range of ligand distribution in the human body, PD-1 plays a key role in regulating various immune responses, such as autoimmunity, tumor immunity, and transplantation immunity (Greisen et al., 2014; Herati et al., 2014; Okazaki and Honjo, 2007; Weissferdt et al., 2017).”
BackgroundInfluentialMechanisms of tumor immunotherapy, with a focus on thoracic cancers
Ferro, S., Huber, V., & Rivoltini, L. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.30 · Cited by 13
“Discovered in the early 1990s as molecules involved in T cell growth control and autoimmunity, immune checkpoints such as PD-1 and CTLA-4 have been then found to play a role in feto-maternal tolerance, chronic viral infections and transplantation (24).”
BackgroundStimulatory and Inhibitory Co-signals in Autoimmunity
Okazaki, T., & Okazaki, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_8 · Cited by 12
Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives
Washah, H. N., Salifu, E. Y., Soremekun, O. S., El-Rashedy, A. A. E., Munsamy, G., Olotu, F. A., & Soliman, M. E. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200427113734 · Cited by 13
Scherbaum, W. A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820683-6.00015-4 · Cited by 13
Key Candidate Prognostic Biomarkers Correlated with Immune Infiltration in Hepatocellular Carcinoma
Deng, Z., Huang, K., Liu, D., Luo, N., Liu, T., Han, L., Du, D., Lian, D., Zhong, Z., & Peng, J. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s337067 · Cited by 16
Hecking, T., Thiesler, T., Halbe, J., Otten, L. A., Recker, F., Gevensleben, H., Müller, T., SCHILLER, C., EGGER, E. K., Fimmers, R., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.15606 · Cited by 13
Liu, C., Zhu, S., Dong, Y., Shao, J., Liu, B., & Shen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930096 · Cited by 15
Wang, W., Chan, A. M., Qin, Y., Kwong, J. M. K., Caprioli, J., Levinson, R. D., Chen, L., & Gordon, L. K. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.08.008 · Cited by 14
“This has recently becomemore important as a theoretical potential in view of the recent FDA approval for use of designer antibodies to block the PD-1 pathway in cancer therapy; thus raising the possibility that there may be a clinical opportunity to block the PD-1 pathway in the eye, should that prove to be useful in…”
BackgroundGenetic variations of immunoregulatory genes associated with Rasmussen syndrome
Takahashi, Y., Mogami, Y., Mine, J., Imai, K., Koide, Y., Matsuda, K., Akasaka, N., Konishi, T., Imamura, A., & Inoue, Y. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.09.004 · Cited by 12
“PDCD1 deficiency in knockout mice leads o autoimmune disorders, and SNPs have been associated ith several autoimmune disorders (Nishimura et al., 1999; kazaki and Honjo, 2007).”
BackgroundSeto, S., Ohmori, S., Nakamura, H., Hijikata, M., & Keicho, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624072 · Cited by 12
“These gd T cells also expressed Pdcd1 , which encodes programmed cell death-1 (PD-1), an immune checkpoint molecule inhibiting immune responses (39).”
Maitra, S., Bhattacharya, D., Paul, S., Chowdhury, P. G., Mandal, D., Haldar, P. K., Balaraman, A. K., & Bala, A. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230213121803 · Cited by 11
Abramenko, N., Vellieux, F. M. D., Veselá, K., Kejík, Z., Hajduch, J., Masařík, M., Babula, P., Hoskovec, D., Pacák, K., Martasek, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51804-2 · Cited by 16
“PD-1, also known as CD279, is a surface transmembrane glycoprotein and a member of the CD28 family 12 .”
BackgroundSun, P., Mo, C., Bai, L., Wang, M., Chen, Z., Zhang, M., Han, Y., Liang, H., & Tang, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107193 · Cited by 12
Targeting PD-1 post-translational modifications for improving cancer immunotherapy
Shi, J., He, C., Chen, L., Xing, X., Wei, W., & Zhang, J. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100248 · Cited by 13
“PD-1, also known as CD279, is a co-inhibitory immune checkpoint protein and classi fi es as a member of the CD28 immunoglobulin super-family (CARRENO & COLLINS, 2002; OKAZAKI & HONJO, 2007).”
Preliminary report: one of the PD-1 gene variants may be a valuable marker for colorectal cancer
Lamami, Y., Mesediyeva, R., Arıkan, S., Ercan, Ş., Kıyan, H. F., Tatar, C., Nayci, A. E., Farooqi, A. A., Yaylım, İ., & Kıran, B. (2018) · Archives of Medical Science - Civilization Diseases · doi:10.5114/amscd.2018.75533 · Cited by 12
“The programmed death 1 (PD-1) gene is located on human chromosome 2 on a segment (2q33~q37) encoding a 50–55 KD a type I transmembranous glycoprotein [11], and containing many other regulatory genes, for instance CTLA-4 and CD28 [12–15].”
BackgroundJomrich, G., Kollmann, D., Ramazanova, D., Ristl, R., Grose, R. P., Ilhan‐Mutlu, A., Preusser, M., Fassnacht, C., Tsai, Y.-C., Guenova, E., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.08.016 · Cited by 12
Chauhan, M. Z., Mansour, H. A., Zafar, M. K., & Uwaydat, S. H. (2022) · Cureus · doi:10.7759/cureus.21709 · Cited by 11
“The central function of PD-1 is to maintain peripheral tolerance through its interaction with PD-L1 (Figure 2A) [10].”
Kondo, Y., Suzuki, S., Ono, S., Goto, M., Miyabe, S., Ogawa, T., Tsuchida, H., Ito, H., Takahara, T., Satou, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084077 · Cited by 12
“2022, 23, 4077 2 of 12 be an important molecule for effector T-cell suppression and PD-L1 in cancer cells, and stromal cells interact with programmed death-1 (PD-1) in effector T-cells, which results in the suppression of cancer immunity [3,4].”
BackgroundLncRNA and its role in gastric cancer immunotherapy
Zhang, Q., Wang, C., Yang, Y., Xu, R., & Li, Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1052942 · Cited by 14
“The PD-1 receptor on the surface of T cells binds to the PD-L1 ligand expressed on the surface of tumor cells, inhibiting the activation and proliferation of T cells, leading to tumor cells produce immune escape (Okazaki and Honjo, 2007).”
BackgroundIntact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein
Tit-oon, P., Wonglangka, A., Boonkanta, K., Ruchirawat, M., Fuangthong, M., Sasisekharan, R., & Khongmanee, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-36203-3 · Cited by 11
“The binding of PD-1 and its ligands downregulates the antigen receptor signaling of the effector T cells to prevent unnecessary immune responses, thereby playing a crucial role in autoimmunity, allergy, transplantation immunity, infectious immunity, and cancer immunity 1,6 .”
BackgroundInfluentialHuang, Y., Yoon, C. H., Gandhi, A. K., Hanley, T., Castrillon, C. E., Kondo, Y., Lin, X., Kim, W., Yang, C., Driouchi, A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00525-8 · Cited by 11
“InadditiontoPD-L1 and PD-L2 5 , it has recently been recognized that human carcinoem-bryonicantigencelladhesionmolecule1(CEACAM1)maybindtoPD1 6 ,in addition to its role as a homophilic ligand and receptor for a variety of microbes 7 and T cell immunoglobulin and mucin domain-containing protein3…”
BackgroundAbdel‐Mohsen, M. A., Toson, E. A., & Helal, M. A. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27713 · Cited by 11
“Program death protein‐1 (PD‐1) is an immune checkpoint receptor that prevents overstimulation of immune responses and contributes to the maintenance of immune tolerance to self‐antigens.(28) HCC‐1806 cells in fully supplemented DMEM were seeded into a flat‐bottom plate, 1 × 10(6) cells/well, for 24 hours.”
BackgroundAcheampong, E., Spencer, I., Lin, W., Ziman, M. R., Millward, M., & Gray, E. S. (2019) · Cancers · doi:10.3390/cancers11070920 · Cited by 11
“As PD-L1 is expressed in both lymphoid and non-lymphoid tissues, it is thought that the interaction between PD-1 and PD-L1 regulates immune responses in both secondary lymphoid organs and target organs [9].”
Background
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.